Ionis Pharmaceuticals (IONS) Scheduled to Post Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) will be announcing its earnings results before the market opens on Wednesday, November 6th. Analysts expect the company to announce earnings of ($1.16) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Ionis Pharmaceuticals Trading Down 0.8 %

Shares of NASDAQ:IONS opened at $38.44 on Tuesday. The company has a current ratio of 7.61, a quick ratio of 7.51 and a debt-to-equity ratio of 4.67. The stock has a market capitalization of $5.62 billion, a PE ratio of -15.25 and a beta of 0.39. The firm has a fifty day moving average price of $41.45 and a 200 day moving average price of $43.00. Ionis Pharmaceuticals has a 1 year low of $35.95 and a 1 year high of $54.44.

Analysts Set New Price Targets

IONS has been the topic of several analyst reports. BMO Capital Markets downgraded Ionis Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $67.00 to $60.00 in a report on Friday, August 2nd. JPMorgan Chase & Co. upped their price objective on shares of Ionis Pharmaceuticals from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Monday, August 26th. Guggenheim decreased their target price on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, October 9th. Leerink Partnrs upgraded Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 24th. Finally, Leerink Partners upgraded Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $53.00 to $62.00 in a research report on Wednesday, July 24th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Ionis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.00.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.